Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer
Journal of Labelled Compounds and Radiopharmaceuticals · 2025
DOI: 10.1002/jlcr.4154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Xiang-Sheng Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear-Agricultural Science, Key Laboratory of Nuclear Agricultural Sciences of Ministry of Agriculture, Zhejiang University, Hangzhou,…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carbon Radioisotopes, Receptors, Androgen, Piperazines. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Key Project of Special Development Foundation of Shanghai Zhangjiang National Innovation Demonstration Zone.
Abstract (Originalsprache)
N ‐((1 R ,4 R )‐4‐(3‐Chloro‐4‐cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide (ARV‐110) is a proteolysis‐targeting chimera (PROTAC) designed against the androgen receptor (AR), which shows great potential for treating AR‐dependent diseases, such as prostate cancer. To support preclinical safety evaluations as well as studies of drug metabolism and pharmacokinetics, two versions of carbon‐14‐labeled ARV‐110 were synthesized: N ‐((1 R ,4 R )‐4‐(3‐chloro‐4‐cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐[1,3‐ 14 C2]dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide ( 14 C‐ARV‐110‐ a ) and N ‐((1 R ,4 R )‐4‐(3‐chloro‐4‐[ cyano ‐ 14 C]cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide ( 14 C‐ARV‐110‐ b ). The synthesis of 14 C‐ARV‐110‐ a was initiated from 1,2‐dibromo‐4,5‐difluorobenzene and zinc cyanide‐ 14 C (Zn( 14 CN)₂), while 14 C‐ARV‐110‐ b was prepared from 2‐chloro‐4‐fluoro[ cyano ‐ 14 C]benzonitrile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nuclear-Agricultural Science, Key Laboratory of Nuclear Agricultural Sciences of Ministry of Agriculture, Zhejiang University, Hangzhou, China.
- Science & Technology Innovation Center, Zhejiang Isotope Technologies Co., Ltd, Hangzhou, Zhejiang Province, China.
- Zhejiang Isotope Labeled Compounds Co., Ltd, Jiaxing, Zhejiang Province, China.
ORCID-Profile: Lei Xu
Förderung
- Key Project of Special Development Foundation of Shanghai Zhangjiang National Innovation Demonstration Zone
Zitieren
APA
Dai, X. S., Dong, B., Xu, L., & Yang, Z. M. (2025). Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4154
Vancouver
Dai XS, Dong B, Xu L, Yang ZM. Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4154
BibTeX
@article{Dai2025,
author = {Dai, Xiang-Sheng and Dong, Bin and Xu, Lei and Yang, Zheng-Min},
title = {Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2025},
doi = {10.1002/jlcr.4154}
}
EUVIMED